SSRI Use in Pregnancy
She stopped her antidepressant the day the pregnancy test came back positive — the relapse risk that decision carries turns out to be the bigger question than the medication ever was.
E.S., a 31-year-old elementary school teacher who is now ten weeks pregnant with her first child, has a history of two prior depressive episodes, both of which responded well to sertraline, most recently maintained at 100mg for the past two years in sustained remission. The day her home pregnancy test came back positive, three weeks ago, she stopped the medication on her own without discussing it with anyone first, out of a fear — one she says she'd absorbed from friends and online forums rather than from any conversation with a clinician — that any medication at all during pregnancy was inherently dangerous to the baby.
In the three weeks since, her sleep has fragmented, her appetite has dropped, and she describes a return of the same hopeless, flat mood that marked the beginning of both prior episodes; her PHQ-9 today is 17, up from 3 at her last visit before the positive test. She has no other chronic illness and no pregnancy complications identified so far on early prenatal screening.
The actual pharmacology here is more specific than 'SSRIs in pregnancy' as a single question. Paroxetine carries a real, replicated signal for fetal cardiac malformations with first-trimester exposure and is generally avoided in pregnancy for that reason; the broader SSRI class carries a separate, much smaller absolute risk of persistent pulmonary hypertension of the newborn with continued use into the third trimester, on the order of one to two additional cases per thousand exposed pregnancies above a baseline of roughly two per thousand. Neither of those is the question this team is actually weighing, since she isn't on paroxetine and hasn't reached the third trimester — the decision in front of them is whether restarting sertraline now, given a well-documented relapse risk on the order of two-thirds for women with recurrent depression who discontinue medication during pregnancy, outweighs a teratogenic risk profile that, for sertraline specifically, has not shown the same cardiac signal paroxetine carries across multiple large cohort studies.
At the obstetric-psychiatric consultation
I want to correct the framing she's carrying in, not just treat the depression — she stopped sertraline specifically, not 'antidepressants' as an undifferentiated category, and sertraline hasn't shown the cardiac malformation signal that paroxetine has across the large cohort studies that actually looked for it. The risk conversation she needs is about the drug she was actually on, not the worst-case version she picked up secondhand.
Agreed on sertraline specifically, and I'd add that the PPHN signal, and the poor neonatal adaptation syndrome that shows up more commonly than PPHN does — jitteriness, feeding difficulty, respiratory distress in the first days, self-limited — are both third-trimester-exposure questions and don't apply to a decision being made at ten weeks gestation. That's a real consideration to revisit later in pregnancy, not a reason to withhold treatment now.
Untreated depression in pregnancy carries its own documented obstetric risks — preterm birth, low birth weight, and impaired engagement with prenatal care among them — which have to sit on the same side of this decision as any medication risk, not be treated as the automatically safer default.
Her relapse risk off medication, given two prior episodes and an early, real recurrence three weeks after stopping, is the dominant number in this decision — roughly two in three women with recurrent depression relapse during pregnancy after discontinuing. Restarting sertraline at her prior effective dose is the option best supported by both her own treatment history and the comparative risk data for this specific drug.
Sertraline was restarted at 100mg, her previously effective dose, with concurrent psychotherapy referral and a plan to revisit the third-trimester conversation — PPHN and neonatal adaptation both — as she approaches that window, rather than folding it into today's decision.
E.S. left with a written summary distinguishing paroxetine's cardiac signal from sertraline's comparative safety profile — the team's explicit goal was replacing the secondhand blanket fear she arrived with with the actual, drug-specific risk information relevant to her own treatment.